Resources:
Bempedoic acid's safety profile
Esperion's plan to launch bempedoic acid
Current recommendations to treat elevated LDL-C
Bempedoic Acid Is Likely To Procure $1B Per Annum
Esperion Therapeutics (ESPR) is nearing the marketization of bempedoic acid [BA] for LDL-C lowering in statin-resistant and intolerant populations. BA is an oral ATP Citrate Lyase Inhibitor. BA uses the same pathway that statins utilize to reduce cholesterol. BA "is specifically designed to avoid myalgias, one of the possible side effects of statin therapy. Though bempedoic acid works in the same cholesterol synthesis pathway as